SK Biopharmaceuticals Signs 48.3 Billion Won Pharmaceutical Supply Contract

On the 24th, SK Biopharmaceuticals announced that it had signed a pharmaceutical supply contract worth 48.3 billion won with its U.S. subsidiary, SK Life Science. This amount is equivalent to 8.8% of its 2024 consolidated sales of 547.6 billion won.

The contract is for supplying products to the subsidiary for the sale of cenobamate, a new antiepileptic drug, in the U.S. market. Because the counterparty is a subsidiary, the transaction is an internal one and will not be reflected as revenue in the consolidated financial statements.

The contract period runs from the 24th through the 26th.

This content was produced with the assistance of AI translation services.